Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates
06:50pm, Tuesday, 25'th Feb 2025
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.02 per share a year ago.
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
04:01pm, Tuesday, 25'th Feb 2025
ROCKVILLE, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
04:00pm, Monday, 24'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NA
Supernus Pharmaceuticals ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
03:30pm, Monday, 24'th Feb 2025
BOSTON, MA / ACCESS Newswire / February 24, 2025 / Block & Leviton is investigating Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) for potential securities law violations. Investors who have lost money
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SUPN
07:30am, Monday, 24'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NA
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NA
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NA
BOSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential securities law violations. Investors who have lost money in their
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
10:29am, Wednesday, 19'th Feb 2025
On Tuesday, Supernus Pharmaceuticals, Inc. SUPN revealed the topline data from the Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD).
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
04:25pm, Tuesday, 18'th Feb 2025
ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade
01:06pm, Thursday, 06'th Feb 2025
Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease
09:00am, Tuesday, 04'th Feb 2025
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada
04:30pm, Monday, 16'th Dec 2024
MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
05:00pm, Tuesday, 26'th Nov 2024
ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
